Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Table 1dProperties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus Class Compound(s) Cellular mechanism
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Antihyperglycemic therapy in type 2 diabetes: general recommendations. Moving from the top to the bottom of the figure, potential sequences of antihyperglycemic therapy. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis (unless there are explicit contraindications). If the HbA1c target is not achieved after ∼3 months, consider one of the five treatment options combined with metformin: a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin. (The order in the chart is determined by historical introduction and route of administration and is not meant to denote any specific preference.) Choice is based on patient and drug characteristics, with the over-riding goal of improving glycemic control while minimizing side effects. Shared decision making with the patient may help in the selection of therapeutic options. The figure displays drugs commonly used both in the U.S. and/or Europe. Rapid-acting secretagogues (meglitinides) may be used in place of sulfonylureas. Other drugs not shown (α-glucosidase inhibitors, colesevelam, dopamine agonists, pramlintide) may be used where available in selected patients but have modest efficacy and/or limiting side effects. In patients intolerant of, or with contraindications for, metformin, select initial drug from other classes depicted and proceed accordingly. In this circumstance, while published trials are generally lacking, it is reasonable to consider three-drug combinations other than metformin. Insulin is likely to be more effective than most other agents as a third-line therapy, especially when HbA1c is very high (e.g., ≥9.0%). The therapeutic regimen should include some basal insulin before moving to more complex insulin strategies (Fig. 3). Dashed arrow line on the left-hand side of the figure denotes the option of a more rapid progression from a two-drug combination directly to multiple daily insulin doses, in those patients with severe hyperglycemia (e.g., HbA1c ≥10.0–12.0%). DPP-4-i, DPP-4 inhibitor; Fx's, bone fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; HF, heart failure; SU, sulfonylurea. aConsider beginning at this stage in patients with very high HbA1c (e.g., ≥9%). bConsider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas. cSee Table 1 for additional potential adverse effects and risks, under “Disadvantages.” dUsually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents. eCertain noninsulin agents may be continued with insulin (see text). Refer to Fig. 3 for details on regimens. Consider beginning at this stage if patient presents with severe hyperglycemia (≥16.7–19.4 mmol/L [≥300–350 mg/dL]; HbA1c ≥10.0–12.0%) with or without catabolic features (weight loss, ketosis, etc.).](https://figures.cochat.ai/paper-figures/128f54a8a50241f9bf5b53c4e153f5da/management-of-hyperglycemia-in-type-2-diabetes-a-patient-centered-approach-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prolonged follow up showed that in some instances the benefit is retained for 10 years or more153–155”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Relationship of glycemic control to outcomes It is well established that the risk of microvascular and macrovascular complications is related to glycemia, as measured by HbA1c; this remains a major focus of therapy (29).”
BackgroundThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Research works printed but not linked: 3
- Berard, 2008, Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, Canadian Journal of Diabetes, 32, S1
- NICE, 2009, Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87
- Committee on Quality of Health Care in America, 2001, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century
Cited by
Items 201–255 of 255
Diabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50
Newman, A. A., Grimm, N. C., Wilburn, J. R., Schoenberg, H. M., Trikha, S. R. J., Luckasen, G. J., Biela, L. M., Melby, C. L., & Bell, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01741 · Cited by 50
Sakaguchi, K., Hirota, Y., Hashimoto, N., Ogawa, W., Hamaguchi, T., Matsuo, T., Miyagawa, J.-I., Namba, M., Sato, T., Okada, S., et al. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700313 · Cited by 50
Improved glucose metabolism after gastric bypass: evolution of the paradigm
Pournaras, D. J., Nygren, J., Hagström-Toft, E., Arner, P., le Roux, C. W., & Thorell, A. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.03.020 · Cited by 48
Jung, H. Y., Lee, H., & Park, J. (2015) · Nursing & Health Sciences · doi:10.1111/nhs.12229 · Cited by 48
Cai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Hossain, M. A., & Pervin, R. (2018) · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome · doi:10.1016/b978-0-12-812019-4.00034-9 · Cited by 47
Mitchell, B. D., He, X., Sturdy, I. M., Cagle, A. P., & Settles, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15831.or · Cited by 46
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Camargos, A. P., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · doi:10.1101/2024.02.05.24302354 · Cited by 46
Sharp, L. K., Tilton, J. J., Touchette, D. R., Xia, Y., Mihailescu, D., Berbaum, M. L., & Gerber, B. S. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2058 · Cited by 45
Vora, J., Cohen, N., Evans, M., Hockey, A., Speight, J., & Whately‐Smith, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12528 · Cited by 44
Malmenäs, M., Bouchard, J. R., & Langer, J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.021 · Cited by 43
Slabaugh, S. L., Bouchard, J. R., Li, Y., Baltz, J. C., Meah, Y. A., & Moretz, D. C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0266-5 · Cited by 41
Öberg, U., Isaksson, U., Jutterström, L., Orre, C. J., & Hörnsten, Å. (2018) · JMIR Diabetes · doi:10.2196/diabetes.9059 · Cited by 41
Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
Ahmann, A., Szeinbach, S. L., Gill, J., Traylor, L., & Garg, S. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0172 · Cited by 39
Hypoglycemia: Minimizing its impact in type 2 diabetes
Moghissi, E., Ismail-Beigi, F., & Devine, R. C. (2013) · Endocrine Practice · doi:10.4158/ep13005.ra · Cited by 39
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163350 · Cited by 38
Yoshida, Y., Cheng, X., Shao, H., Fonseca, V. A., & Shi, L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-1292-5 · Cited by 39
de Carvalho, G. B., Dias-Vasconcelos, N. L., Santos, R. K. F., Brandão-Lima, P. N., da Silva, D. G., & Pires, L. V. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1624498 · Cited by 38
Xie, X., Liao, J., Ai, Y., Gao, J., Zhao, J., Qu, F., Xu, C., Zhang, Z., Wen, W., Cui, H., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.748872 · Cited by 37
Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Continuous Glucose Monitoring in the Self-management of Type 2 Diabetes: A Paradigm Shift
Cox, D. J., Taylor, A. G., Moncrief, M., Diamond, A., Yancy, W. S., Hegde, S., & McCall, A. L. (2016) · Diabetes Care · doi:10.2337/dc15-2836 · Cited by 36
Takeshita, Y., Takamura, T., Kita, Y., Otoda, T., Kato, K., Wakakuri, H., Yamada, M., Misu, H., Matsushima, Y., Kaneko, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12269 · Cited by 35
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“T2DM is initially treated with lifestyle modifications and metformin; however, over time, increasing insulin resistance and declining b-cell mass and function often necessitate escalating therapeutic intervention [14-17].”
BackgroundGerber, B. S., Rapacki, L., Castillo, A., Tilton, J., Touchette, D. R., Mihailescu, D., Berbaum, M. L., & Sharp, L. K. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-891 · Cited by 33
Elissen, A. M. J., Hertroijs, D. F. L., Schaper, N. C., Bosma, H., Dagnelie, P. C., Henry, R. M., van der Kallen, C. J., Koster, A., Schram, M. T., Stehouwer, C. D. A., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182053 · Cited by 31
Schunk, M., Reitmeir, P., Schipf, S., Völzke, H., Meisinger, C., Ladwig, K.-H., Kluttig, A., Greiser, K. H., Berger, K., Müller, G., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.010 · Cited by 31
Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Thyroid safety in patients treated with liraglutide
Gallo, M. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346749 · Cited by 27
Iqbal, S., Jayyab, A. A., Alrashdi, A. M., & Reverté-Villarroya, S. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.01.004 · Cited by 27
Ossenbrink, L., Haase, T., Timpel, P., Schoffer, O., Scheibe, M., Schmitt, J., Deckert, S., & Harst, L. (2023) · JMIR Serious Games · doi:10.2196/44132 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Norwood, P., Liutkus, J. F., Haber, H., Pintilei, E., Boardman, M. K., & Trautmann, M. E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.007 · Cited by 24
Magee, M. F., Nassar, C. M., Mete, M. Y., White, K., Youssef, G. A., & Dubin, J. S. (2015) · Endocrine Practice · doi:10.4158/ep15655.or · Cited by 23
Jin, S., Kim, J. H., Min, K. W., Lee, J. H., Ahn, K. J., Park, J. H., Jang, H. C., Park, S. W., Lee, K. W., Won, K. C., et al. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12312 · Cited by 23
Cox, D. J., Taylor, A. G., Singh, H., Moncrief, M., Diamond, A., Yancy, W. S., Hegde, S., & McCall, A. L. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.021 · Cited by 21
Personalised treatment targets in type 2 diabetes patients: The Dutch approach
Boels, A. M., Hart, H. E., Rutten, G. E., & Vos, R. C. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2016.08.001 · Cited by 20
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Arnold, S. V., McGuire, D. K., Spertus, J. A., Li, Y., Yue, P., Ben-Yehuda, O., Belardinelli, L., Jones, P. G., Olmsted, A., Chaitman, B. R., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.020 · Cited by 19
Wang, Y., Wang, J., Gong, Q., Wu, H., Yang, S., He, J., Hu, X., & Huang, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0384 · Cited by 18
Kim, H. D., Chang, J.-Y., Chung, B. H., Kim, C.-D., Lee, S.-H., Kim, Y. H., & Yang, C. W. (2021) · Annals of Transplantation · doi:10.12659/aot.927984 · Cited by 17
Yu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.001 · Cited by 15
Gajewska, K. A., Biesma, R., Sreenan, S., & Bennett, K. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032916 · Cited by 15
Gebreyesus, H. A., Abreha, G. F., Besherae, S. D., Abera, M. A., Weldegerima, A. H., Kidane, E. G., Bezabih, A. M., Lemma, T. B., & Nigatu, T. G. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00750-5 · Cited by 14
Dalal, M. R., Kazemi, M. R., & Ye, F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1248911 · Cited by 14
Glycaemic management of type 2 diabetes
Srinivasan, B. T., & Davies, M. (2019) · Medicine · doi:10.1016/j.mpmed.2018.10.009 · Cited by 14
Zgibor, J. C., Kuo, S., Emerson, S., Gittinger, P., Solano, F. X., Tilves, D., Maloney, M., & Davidson, M. B. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.07.004 · Cited by 10
Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M., & Davies, M. J. (2014) · Diabetes Care · doi:10.2337/dc14-0165 · Cited by 3
Balkau, B., Halimi, S., Blickle, J.-F., Vergès, B., Avignon, A., Attali, C., Chartier, I., & Amelineau, E. (2016) · Annales d'Endocrinologie · doi:10.1016/j.ando.2016.03.001 · Cited by 3
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Clinic (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands; the
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece; the
- Thomas Jefferson University (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1364-1379
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3357214
- OpenAlex
- W2172193326
- Cited by
- 3,207
- References
- 141
- Citations by year
- 2026: 18 · 2025: 54 · 2024: 72 · 2023: 95 · 2022: 95 · 2021: 119 · 2020: 132 · 2019: 147 · 2018: 218 · 2017: 274 · 2016: 349 · 2015: 477 · 2014: 588 · 2013: 441 · 2012: 124
- FWCI
- 415.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Yale University
- University of Southern California
- University of Miami
- Wayne State University
- Georgetown University
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- MedStar Health Research Institute
- National Institute for Health and Care Research (NF-SI-0508-10272)
- University of Sydney
- University of Melbourne
- University of Toronto
- European Association for the Study of Diabetes
- Université de Nantes
- University of Ioannina
- University of Illinois at Urbana-Champaign
- School of Medicine, University of Kansas
- Health Science Center, University of Tennessee
- Leonard M. Miller School of Medicine
- Leonard M. Miller School of Medicine, University of Miami
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- hyperglycemia management, type 2 diabetes, glucose-lowering agents, patient-centered care, treatment selection
- MeSH terms
- Age Factors, Algorithms, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Kidney Diseases, Liver Diseases, Male, Risk Factors, United States, Patient-Centered Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.